COMBINATION ALZHEIMER THERAPY USING ANTI-N3PGLU ABETA ANTIBODIES + A BACE INHIBITOR
申请人:Eli Lilly and Company
公开号:US20170224702A1
公开(公告)日:2017-08-10
The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti-N3pGlu Abeta monoclonal antibody.